文献速递腹部介入US

使用诊断超声与微泡的声化学治疗不可手术胰腺癌:多中心、开放标签、随机对照试验

Clinical sonochemotherapy of inoperable pancreatic cancer using diagnostic ultrasound and microbubbles: a multicentre, open-label, randomised, controlled trial.
PubMed 文献 · Eur Radiol · 2023-10-05

这项2期多中心开放标签随机对照试验纳入82例III或IV期胰腺导管腺癌患者,78例随机分为化疗组40例和声化学治疗组38例。声化学治疗组中位总生存期9.10个月,化疗组6.10个月(p=0.037);疾病控制率声化学治疗组73.68%,对照组42.50%(p=0.005)。结论认为声化学治疗可延长III或IV期胰腺癌患者生存且不增加严重不良事件。

要点

  • 声化学治疗组中位总生存期9.10个月,化疗组6.10个月,差异有统计学意义(p=0.037)。
  • 声化学治疗组疾病控制率73.68%,化疗组42.50%,差异有统计学意义(p=0.005)。
  • 两组总体不良事件发生率均衡,声化学治疗未增加严重不良事件。

核心结论

  • 声化学治疗可延长III或IV期胰腺癌患者的总生存期和体能状态良好时间,且不增加严重不良事件。

研究设计与样本

  • 多中心、开放标签、随机对照2期临床试验,2018年7月至2021年3月招募82例III或IV期胰腺癌患者,随访至2022年9月,78例随机分配至化疗组40例和声化学治疗组38例;使用改良诊断超声扫描仪在化疗输注后行30分钟超声治疗;主要终点为总生存期。

诊断标准与关键数值

  • 声化学治疗组中位总生存期9.10个月 vs 化疗组6.10个月(p=0.037);声化学治疗组中位无进展生存期5.50个月 vs 化疗组3.50个月(p=0.080);声化学治疗组ECOG评分<2时间7.20个月 vs 化疗组5.00个月(p=0.029);声化学治疗组疾病控制率73.68% vs 对照组42.50%(p=0.005)。

临床应用与阅片要点

  • 原文结论认为声化学治疗可延长III或IV期胰腺癌患者生存和体能状态良好时间,且不增加严重不良事件。

局限性

  • 无进展生存期声化学治疗组5.50个月 vs 化疗组3.50个月,p=0.080,未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Sonochemotherapy, which uses microbubble (MB)-assisted ultrasound (US) to deliver chemotherapeutic agents, has the potential to enhance tumour chemotherapy. The combination of US and MB has been demonstrated to prolong the survival of patients with pancreatic cancer. This phase 2 clinical trial aimed to determine the clinical efficacy and safety of sonochemotherapy for inoperable pancreatic ductal adenocarcinoma by using US and MB.

METHODS: Eighty-two patients with stage III or IV pancreatic cancer were recruited from July 2018 to March 2021 and followed up until September 2022. US treatment was performed with a modified diagnostic US scanner for 30 min after chemotherapeutic infusion. The primary endpoint was overall survival (OS), and the secondary endpoints were Eastern Cooperative Oncology Group (ECOG) status < 2, progression-free survival (PFS), disease control rate (DCR), and adverse events.

RESULTS: Seventy-eight patients were randomly allocated (40 to chemotherapy and 38 to sonochemotherapy). The median OS was longer with sonochemotherapy than with chemotherapy (9.10 vs. 6.10 months; p = 0.037). The median PFS with sonochemotherapy was 5.50 months, compared with 3.50 months (p = 0.080) for chemotherapy. The time of ECOG status < 2 was longer with sonochemotherapy (7.20 months) than with chemotherapy (5.00 months; p = 0.029). The DCR was 73.68% for sonochemotherapy compared with 42.50% for the control (p = 0.005). The incidence of overall adverse events was balanced between the two groups.

CONCLUSIONS: The use of sonochemotherapy can extend the survival and well-being time of stage III or IV pancreatic cancer patients without any increase in serious adverse events.

TRIAL REGISTRATION: ChineseClinicalTrials.gov ChiCTR2100044721 CLINICAL RELEVANCE STATEMENT: This multicentre, randomised, controlled trial has proven that sonochemotherapy, namely, the combination of diagnostic ultrasound, microbubbles, and chemotherapy, could extend the overall survival of patients with end-stage pancreatic ductal adenocarcinoma from 6.10 to 9.10 months without increasing any serious adverse events.

KEY POINTS: • This is the first multicentre, randomised, controlled trial of sonochemotherapy for clinical pancreatic cancer treatment using ultrasound and a commercial ultrasound contrast agent. • Sonochemotherapy extended the median overall survival from 6.10 (chemotherapy alone) to 9.10 months. • The disease control rate increased from 42.50% with chemotherapy to 73.68% with sonochemotherapy.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Han F, Wang Y, Dong X, et al. Clinical sonochemotherapy of inoperable pancreatic cancer using diagnostic ultrasound and microbubbles: a multicentre, open-label, randomised, controlled trial. Eur Radiol. 2023. PMID: 37796294. doi:10.1007/s00330-023-10210-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。